6C1 Stock Overview
An oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CytomX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.78 |
| Beta | 1.06 |
| 11 Month Change | -16.45% |
| 3 Month Change | -21.69% |
| 1 Year Change | -30.72% |
| 33 Year Change | -87.08% |
| 5 Year Change | -85.34% |
| Change since IPO | -91.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6C1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | 0.8% | -1.3% |
| 1Y | -30.7% | -17.5% | 7.4% |
Return vs Industry: 6C1 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 6C1 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 6C1 volatility | |
|---|---|
| 6C1 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6C1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6C1's weekly volatility has decreased from 27% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 121 | Sean McCarthy | www.cytomx.com |
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
CytomX Therapeutics, Inc. Fundamentals Summary
| 6C1 fundamental statistics | |
|---|---|
| Market cap | €64.96m |
| Earnings (TTM) | €13.19m |
| Revenue (TTM) | €120.79m |
4.9x
P/E Ratio0.5x
P/S RatioIs 6C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6C1 income statement (TTM) | |
|---|---|
| Revenue | US$126.62m |
| Cost of Revenue | US$0 |
| Gross Profit | US$126.62m |
| Other Expenses | US$112.79m |
| Earnings | US$13.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | 10.92% |
| Debt/Equity Ratio | 0% |
How did 6C1 perform over the long term?
See historical performance and comparison